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Abstract Post-translational modifications (PTMs) of
proteins induce structural and functional changes that are
most often transitory and difficult to follow and inves-
tigate in vivo. In silico prediction procedures for PTMs
are very valuable to foresee and define such transitory
changes responsible for the multifunctionality of pro-
teins. Epidermal growth factor receptor (EGFR) is such a
multifunctional transmembrane protein with intrinsic
tyrosine kinase activity that is regulated primarily by
ligand-stimulated transphosphorylation of dimerized
receptors. In human EGFR, potential phosphorylation
sites on Ser, Thr and Tyr residues including five auto-
phosphorylation sites on Tyr were investigated using
in silico procedures. In addition to phosphorylation, O-
GlcNAc modifications and interplay between these two
modifications was also predicted. The interplay of
phosphorylation and O-GlcNAc modification on same or
neighboring Ser/Thr residues is termed as Yin Yang
hypothesis and the interplay sites are named as Yin
Yang sites. Amongst these modification sites, one residue
is localized in the juxtamembrane (Thr 654) and two are
found in the catalytic domain (Ser 1046/1047) of the
EGFR. We propose that, when EGFR is O-GlcNAc
modified on Thr 654, EGFR may be transferred from
early to late endosomes, whereas when EGFR is O-
GlcNAc modified on Ser 1046/1047 desensitization of
the receptor may be prevented. These findings suggest a
complex interplay between phosphorylation and O-Glc-
NAc modification resulting in modulation of EGFR’s
functionality.
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Introduction
Different PTMs, such as phosphorylation and O-GlcNAc
modification are major regulators of protein function.
When receptor tyrosine kinases (RTKs) become active,
they phosphorylate a series of cytoplasmic substrate pro-
teins that in turn become activated. Receptor kinases are
activated by physiological receptor agonists and overex-
pression or mutations causing constitutive activation of the
receptor can lead to uncontrolled RTK signaling and
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subsequent development and progression of certain types
of cancers [1, 2].
The epidermal growth factor receptor (EGFR) is a
receptor tyrosine kinase that regulates fundamental pro-
cesses of cell growth and differentiation [3]. EGFR is a
transmembrane protein that binds to its cognate ligand such
as epidermal growth factor (EGF) or transforming growth
factor-a (TGF-a). Consequently, the EGFR undergoes
dimerization that stimulates its intrinsic Tyrosine kinase
activity in its cytoplasmic tail [3]. Activation of RTK
results in autophosphorylation of EGFR’s C-terminal,
which contains 3 major autophosphorylation sites (Tyr
1068, 1148 and 1173) [4] and 2 minor autophosphorylation
sites (Tyr 992 [5] and Tyr 1086 [6]). Autophosphorylation
of the EGFR provides docking sites for signal/adaptor
proteins, like phospholipase Cc, growth factor receptor
binding protein 2 (Grb2) and the adaptor protein Shc [3].
Binding of these signal/adaptor proteins to the EGFR starts
the signal transduction cascade, which eventually leads to
activation of transcription in the nucleus [3].
Cellular activation via the EGFR increases cytosolic
calcium [7]. This rise in calcium inhibits EGFR’s intrinsic
RTK activity. The activation of the calcium/calmodulin
dependent Ser/Thr protein kinase-II (CaM-II) inhibits
RTK by phosphorylating EGFR on Ser 1046/1047 in
EGFR’s catalytic domain [7]. Phosphorylation of EGFR
on Ser 1046/1047 by CaM-II leads to desensitization of
EGFR, lowering the affinity of the receptor for its ligand,
in EGF simulated cells [8], and contributes to transacti-
vation of the EGFR [7]. The protein calmodulin (CaM)
binds to EGFR in the juxtamembrane portion and inhibits
its RTK activity [7]. When CaM binds to EGFR, it pre-
vents protein kinase C (PKC) from phosphorylating
EGFR [9, 10]. The phosphorylated EGFR on Thr 654 by
PKC in the juxtamembrane domain promotes recycling of
endocytosed receptors back to the cellular surface,
thereby maintaining EGFR signaling in cells [11],
whereas, the EGFR bound to CaM is prevented from
recycling after endocytosis [9, 10]. Furthermore, phos-
phorylation of EGFR by mitogen activated protein kinase
(MAPK) and protein kinase A (PKA) transmodulates
EGFR by decreasing the activity of its intrinsic Tyrosine
kinase [12–14]. MAPK phosphorylates EGFR on Thr 669
[13, 15, 16] and is activated either through the Ras/
MAPK signaling pathway [3] or through transactivation
of the EGFR by PKC [17]. It thus appears that several
kinases work together to ensure non-constitutive signaling
by EGFR.
An equally important and dynamic PTM, the O-Glc-
NAc modification, is detectable in nearly all higher
eukaryotic organisms [18]. It is an ubiquitous modifica-
tion that is regulated by O-GlcNAc transferase (OGT)
(adds O-GlcNAc to protein backbone) and O-GlcNAcase
(OGN) (removes O-GlcNAc from protein backbone).
Compared to other O-linked glycosylation processes such
as O-GalNAc modification, O-GlcNAc modification
involves a single sugar residue modification. Complex
interplay between phosphorylation and O-GlcNAc modi-
fication on the same or neighboring residues, the yin-yang
sites, has been observed in several nuclear and cytoplas-
mic proteins [19], and evidence of O-GlcNAc
modification in EGFR type III has been experimentally
verified [20]. This alternative modification of Ser/Thr
residues by O-GlcNAc and phosphate often results in
functional switches of a protein.
Computer-assisted methods are useful in assessing the
modification potential of a given protein [21]. Prediction of
modification and experimental authentification is only
possible where the half-life and availability of protein
allows it. The computer assisted procedures are necessary
where condition of limited availability and instability of
proteins prevail for transitorily-modified proteins to per-
form diverse functions. Computational procedures have
played an important role in understanding genomics, pro-
teomics and defining the contribution of phosphorylation,
sulfation and glycosylation in various contexts of func-
tional protein regulation. Programs based on artificial
neural networks have been applied to predict glycosylation
and phosphorylation sites in proteins with reliable accuracy
[21]. The interplay between phosphorylation and O-Glc-
NAc modification results in temporary structure–function
changes. Assessing these temporary structural changes
induced by modifications, in vivo, is not possible with the
existing methodology. Protein functional information can
be deduced from their 3-D structures. However, determi-
nation of the 3-D structure in vivo is difficult because of
constant intra- and inter-molecular interactions occurring
between proteins in body fluids or in the cell. Most of the
structural data available in protein databases is only par-
tially relevant to the dynamic behavior of proteins in vivo.
Defining protein functions in physiological environments
remains a daunting task due to the presence of innumerable
other molecules that constantly interact with the test
protein.
Evolutionarily-conserved residues have been found to
be functionally important [22]. Interplay of phosphoryla-
tion and O-GlcNAc modification on conserved Ser/Thr
residues in histone H3 [23] and other proteins [24, 25] has
been documented.
In this study we have identified Yin Yang sites in human
EGFR utilizing in silico procedures. We propose that an
interplay between phosphorylation and O-GlcNAc modi-
fication on Ser and Thr residues in the juxtamembrane and
in the C-terminal region of the EGFR occurs, suggesting an
important role of OGT in the functional regulation of
human EGFR.
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Materials and methods
Sequence data
The sequence data, for prediction of phosphorylation and
O-GlcNAc modification sites in EGFR (Homo sapiens),
was retrieved from Swiss-Prot sequence database, with the
entry name EGFR_HUMAN and primary accession no.
P00533 [26]. BLAST search was performed using the
NCBI database for all known organisms’ sequences [27]. A
total of 1561 hits were obtained and the sequences with the
highest bits score and zero expect values were selected to
locate conserved Ser/Thr and Tyr residues of the EGFR.
The chosen sequences, including that of human EGFR,
were multiply aligned using ClustalW [28], a multiple
sequence alignment program for DNA or proteins. The five
sequences selected were from Mus musculus (RefSeq.
AAG24386.1), Rattus norvegicus (RefSeq. NP_113695.1),
Sus scrofa (RefSeq. NP_999172.1), Danio rerio (RefSeq.
NP_919405.1) and Xiphophorus xiphidium (RefSeq.
AAP55673.1).
PTMs prediction methods
Artificial neural network based prediction methods are
generally used in biological sequence analysis of proteins.
Neural networks are composed of a large number of
highly interconnected processing elements (simulated
neurones) that work in parallel to solve a complex
problem. These networks are trained by sequence patterns
of modified and non-modified proteins so that they
become able to recognize and predict a pattern in a new
protein for their potential of modification. Artificial neural
networks receive many inputs and give one output as a
result. NetPhos 2.0 [29] was developed by training the
neural networks with phosphorylation data from Phos-
phobase 2.0 [30]. A threshold value of 0.5 is used by
Netphos 2.0 to determine possible potential for phos-
phorylation. Netphos 2.0 (http://www.cbs.dtu.dk/services/
Netphos/) was utilized to predict potential phosphoryla-
tion sites in human EGFR.
YinOYang 1.2 employs the sequence data to train a jury
of neural networks on 40 experimentally determined O-
GlcNAc acceptor sites for recognizing the sequence con-
text and surface accessibility. The method has the
capability to predict the sites known as Yin Yang sites that
can be O-GlcNAc modified and alternatively phosphory-
lated. The threshold value used by YinOYang 1.2 varies
depending upon surface accessibility of the different amino
acid residues. To predict potential of O-GlcNAc modifi-
cation and Yin Yang sites in human EGFR YinOYang 1.2
(http://www.cbs.dtu.dk/services/YinOYang/) (unpublished)
was used.
NetphosK 1.0 (http://www.cbs.dtu.dk/services/NetPhosK/)
[31] was used to predict the potential of kinases most likely
to phosphorylate Ser, Thr and Tyr in human EGFR.
Comparison of human OGT’s sequence with EGFR’s
autophosphorylation sites
The comparison of the sequence environment in human
OGT with the sequence environment of EGFR’s auto-
phosphorylation sites was performed. OGT’s sequence was
retrieved from the Swiss-Prot sequence database [26] with
the entry name OGT1_HUMAN and primary accession no.
O15294. The protein sequence of OGT in rat was aligned
with that of human OGT to determine the position of Tyr
979 of rat OGT to human OGT.
Results
Phosphorylation and O-GlcNAc modification
in human EGFR
Prediction results of human EGFR by Netphos 2.0 of Ser, Thr
and Tyr are given in Fig. 1a and in Table 1. These results
show a high phosphorylation potential in human EGFR.
Prediction of possible O-GlcNAc modification in human
EGFR by YinOYang 1.2 is given in Table 1 and in Fig. 1b.
Yin Yang sites in EGFR
The prediction results for Yin Yang sites in EGFR by
YinOYang 1.2 are illustrated in Fig. 1c and given in
Table 2. In several cases Ser and Thr residues show a very
high potential for either O-GlcNAc modification or phos-
phorylation or show a potential very close to the specific
threshold value predicted by the existing methods. When a
conserved residue shows a very high potential for phos-
phorylation and a potential for O-GlcNAc modification
very close to the threshold value it appears to be a false
negative Yin Yang site as on these sites OGT and kinases
may have an equal accessibility to modify a specific site.
The in silico predicted Yin Yang sites, Thr 1005 and Ser
1006, and the false negative Yin Yang site, Thr 654, were
fully conserved in mammals and in pisces (Fig. 2). The
other predicted Yin Yang sites, Ser 1046/1047 and Ser
1180, were fully conserved in mammals (Fig. 2).
Autophosphorylation of the EGFR
All potential predicted Tyr autophosphorylation sites
(Table 3) were found to be conserved in mammals and
pisces, except Tyr 1086 which has been mutated to Gly in
pisces (Fig. 2). The predicted autophosphorylated Tyr
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residues (Tyr 992, 1068, 1086, 1148 and 1173) are located
in the cytoplasmic tail of EGFR, which is downstream the
RTK domain, and is in the catalytic domain of the EGFR.
The results of NetphosK 1.0, for predicting the potential of
kinases involved in the EGFR’s autophosphorylation sites,
show that EGFR is the only potential kinase to modify
these sites (Table 3, Fig. 3).
Fig. 1 (a) Graphic presentation
of the potential phosphate
modification on Ser and Thr
residues in human EGFR. The
blue vertical lines show the
potential phosphorylated Ser
residues; the green lines show
the potential phosphorylated
Thr residues; the red line show
the potential phosphorylated
Tyr residues. The light grey
horizontal line shows threshold
for modification potential. (b)
Graphic representation of
potential for O-GlcNAc
modification of Ser and Thr
residues in human EGFR. The
green vertical lines show the
O-GlcNAc potential of Ser/Thr
residue and light blue horizontal
wavy line shows threshold for
modification potential. (c)
Graphic representation of
potential Yin Yang sites in
human EGFR. The green
vertical lines show the O-
GlcNAc potential of Ser/Thr
residue and light blue horizontal
wavy line shows threshold for
modification potential. The red
asterisk shows the potential Yin
Yang sites in human EGFR
Table 1 In silico predicted
phosphorylation- and O-
GlcNAc modification sites
in human EGFR
Predicted phosphorylation sites Ser 99, 203, 205, 222, 262, 291, 356, 428, 433, 460, 474, 506, 728,
744, 933, 967, 1002, 1004, 1006, 1013, 1018, 1046, 1047, 1057,
1080, 1125, 1142, 1166, 1180
Thr 235, 373, 548, 654, 669, 701, 727, 868, 916, 1005, 1107
Tyr 45, 64, 89, 93, 261, 292, 447, 561, 586, 602, 740, 777, 845, 992,
1068, 1086, 1101, 1114, 1148, 1173
Predicted glycosylation sites Ser 146, 196, 501, 897, 1006, 1046, 1047, 1096, 1106, 1180, 1181
Thr 278, 1005, 1008, 1121
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Comparison of OGT’s sequence with EGFR’s
autophosphorylation sites
When the sequence of OGT in rat was aligned with the
sequence of OGT in human, it was found that Tyr 979 in
rat OGT corresponds to Tyr 989 in human OGT. The
sequence motif of the predicted autophosphorylation sites
in EGFR was compared with the sequence motif of Tyr 989
in human of OGT. These results showed that three out of
five EGFR autophosphorylation sites have a similar
sequence to that of OGT around Tyr 989 (Fig. 4).
Discussion
Phosphorylation of EGFR is the primary mechanism in the
regulation of its RTK activity, and contributes significantly
to the process of the signal transduction. A complex
interplay between phosphorylation and O-GlcNAc modi-
fication leads to functional changes of the EGFR that either
diverts EGFR toward degradation or altogether prevents it.
Autophosphorylation sites of the human EGFR were
predicted to be Tyr 992, 1068, 1086, 1148 and 1173
(Table 3), which is in agreement with experimentally
verified data [4–6]. These sites were also correctly
Table 2 In silico predicted
Yin Yang and false-negative
sites in human EGFR
False-negative site Thr 654
Yin Yang sites Thr 1005
Ser 1006
Ser 1046
Ser 1047
Ser 1180
Fig. 2 Multiple alignments of
EGFR sequences of four
mammals (Homo sapiens, Mus
musculus, Rattus norvegicus
and Sus scrofa) and two pisces
(Danio rerio and Xiphophorus
xiphidium). The consensus
sequence is marked by an
asterisk, conserved substitution
by a double dot, semiconserved
substitution by a single dot and
deletion gaps by a small single
line. The different sequences are
ordered as in aligned results
from ClustalW. The positively
predicted Yin Yang sites are
highlighted in green, and the
negatively predicted Yin Yang
site is highlighted in yellow.
Furthermore the predicted
autophosphorylation sites are
highlighted in red
Table 3 In silico predicted autophosphorylation Tyr sites in human
EGFR
Residue NetphosK 1.0 prediction
992, 1068, 1086, 1148, 1173 EGFR
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predicted by the NetphosK 1.0 [31] and suggest their
phosphorylation only by EGFR’s intrinsic RTK (Fig. 3).
Other phosphorylated Tyr residues were predicted to be
potentially phosphorylated by Src protein tyrosine kinase,
which is consistent with Stover et al. [32], who reported
that Src phosphorylates EGFR on several Tyr residues in
its catalytic domain, and thereby provides additional
docking sites for SH2-domain containing proteins.
Normal endocytosis leads to gradual attenuation or
desensitization of receptor signaling or finally to degrada-
tion of the receptor [33]. Activated EGFR is internalized in
coated pits, sorted through early endosomes, where the
ligand is released from the receptor [34]. Finally unoccu-
pied and ligand free EGFR is either recycled back to the
cell surface or ultimately degraded in lysosomes (receptor
termination) [34].
Endosomal sorting of the EGFR depends somewhat of
its intrinsic Tyr kinase activity [35], but in some instances
when RTK’s activity is partially inhibited, ubiquitination of
the receptor can mediate its internalization.
In this in silico study, we have predicted a false-nega-
tive Yin Yang site in the juxtamembrane of the EGFR, Thr
654 (substrate of PKC) (Table 2). Threonine 654 is fully
conserved in mammals, and pisces (Table 2, Fig. 2). When
EGFR is phosphorylated on Thr 654, it prevents transfer of
activated EGFRs from early to late endosomes, and diverts
receptors to recycling via endosomes back to the cellular
surface [11]. c-Cbl is a multi-adaptor protein with E3-
ubiquitin ligase activity that ubiquinates EGFR on several
Lys residues [36], and is essential for lysosomal targeting
of the receptor [37]. The protein c-Cbl binds to the catalytic
domain of the EGFR on phosphorylated Tyr 1045, which in
turn transphosphorylates the c-Cbl protein in its RING
finger domain [35]. The ubiquitin ligase c-Cbl can also
bind indirectly to EGFR by binding to Grb2 via its
C-terminal, but direct binding of c-Cbl to the EGFR is
favored [38]. When EGFR becomes phosphorylated on Thr
654 by PKC, it is no longer able to engage c-Cbl [11].
Furthermore, phosphorylated Thr 654 also prevents bind-
ing of CaM to EGFR’s juxtamembrane domain [9, 10],
suggesting that PKC, CaM and c-Cbl work together to
regulate the activity of EGFR. PKC and PKA are inversely
related to OGT in cerebellar neurons [39]. We suggest,
when Thr 654 is O-GlcNAc modified, EGFR cannot be
Fig. 3 Kinase landscape
prediction for human EGFR
sequence. The E shows where
EGFR’s intrinsic Tyr kinase
phosphorylates EGFR in its
catalytic domain. Is it observed
that only EGFR’s intrinsic Tyr
kinase phosphorylate EGFR on
its autophosphorylation sites.
(A: PKA, C: PKC, G: PKG, K:
CKII, E: EGFR, X: GSK3, X:
p38MAPK)
Fig. 4 Comparison of human OGT sequence around Tyr 989 with
EGFR’s autophosphorylation sites. The yellow highlighted Y shows
the residue in OGT, where phosphorylation occurs. In human EGFR
the highlighted Y’s show the receptors five autophosphorylation sites.
The blue and red residues in human EGFR show the identical or
similar residues as in the human OGT sequence
636 Mol Biol Rep (2009) 36:631–639
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phosphorylated, readily interacts with CaM in the juxta-
membrane portion of the receptor and allows c-Cbl to
interact with the EGFR. This suggests that OGT plays a
role in the lysosomal targeting of EGFR.
The kinase CaM-II phosphorylates Ser 1046/1047 in the
catalytic tail of the EGFR [39]. These sites are of func-
tional importance, because HER2/c-erbB2 (isoform of
EGFR) that does not contain CaM-II phosphorylation sites
in its catalytic domain has been shown to be highly
oncogenic [40]. Phosphorylation on Ser 1046/1047 by
CaM-II inhibits RTK and desensitizes the EGFR [8, 40].
The Ser 1046/1047 residues of human EGFR are positively
predicted Yin Yang sites (Table 2) and OGT may equally
have access to O-glycosylate these residues. Ser 1046/1047
are conserved in mammals (Fig. 2). Increase in intracel-
lular calcium levels activates calcium-dependent kinase,
which reduces O-GlcNAc levels in neurons [39] and
cardiomyocytes [41]. This suggests that inverse relation-
ship between O-GlcNAc levels and calcium may exist.
Furthermore O-GlcNAc modification of Synapsin I inter-
feres with phosphorylation of Synapsin I by CaM-II [42],
suggesting that OGT and CaM-II may work together to
regulate the function of different proteins. Thus, when
calcium levels are low in cells, OGT may add O-GlcNAc
on Ser 1046/1047, and prevent CaM-II from phosphory-
lating EGFR. We propose that a possible interplay between
OGT and CaM-II may either desensitize EGFR when CaM-
II is active or activate EGFR when O-GlcNAc acts on
EGFR (Fig. 5). At the same time PKC may also be mod-
ified by O-GlcNAc, which has been known to become
inactivated by increased intracellular O-GlcNAc incorpo-
ration levels [39, 43] and thus at a time PKC or CaM-II is
available to phosphorylate EGFR.
It is interesting to observe that all positively predicted
Yin Yang sites were in the catalytic domain of the EGFR.
In this domain, second messenger proteins containing
either a SH2-domain or a PTB-domain interact with the
receptor, suggesting that OGT also participates in signal
transduction. It is known that OGT contains multiple tet-
ratricopeptide repeats that mediate the enzyme’s
trimerization, substrate recognition, and protein–protein
interactions [44]. Furthermore, the enzyme is modified by
Tyr phosphorylation as well as O-GlcNAc modification
[45]. The activity of OGT can be regulated by its Tyr
phosphorylation [39] on Tyr 989 in human (corresponding
to 979 in rat) possibly via the Tyr kinase signal
Fig. 5 (a) Upon ligand binding, EGFR’s intrinsic Tyr kinase is
activated, and starts phosphorylation in EGFR’s cytoplasmic tail.
Autophosphorylation of the EGFR triggers the signal transduction.
When EGFR is phosphorylated on Thr 654 by PKC, it prevents
binding of CaM and c-Cbl to the EGFR. Phosphorylated EGFR is
transferred to recycling endosomes from where they return to the cell
surface and maintain cell signal transduction. When Thr 654 is
dephosphorylated, OGT might become phosphorylated by EGFR’s
Tyr kinase. Furthermore OGT O-GlcNAc modifies Thr 654, which
might prevent its recycling and promote transfer of the receptor to late
endosomes. (b) When EGFR is phosphorylated in the cytoplasmic tail
on Ser 1046/1047 by CAM-II, it leads to desensitization of the
receptor, and inhibits its intrinsic Tyr kinase activity. The ligand
unoccupied EGFR becomes target of CaM and c-Cbl. If EGFR is
dephosphorylated on Ser 1046/1047, EGFR is transactivated, and the
ligand binds to the EGFR on the cell surface. PKC phosphorylates the
EGFR and cell signaling continues. If OGT O-GlcNAc modifies Ser
1046/1047 and Thr 654, EGFR interacts with CaM and c-Cbl and
might move into late endosomes
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transduction [45]. When the sequence environment around
Tyr 989 in human OGT was explored, it was found to be
similar to the sequence of three of EGFR’s autophospho-
rylation sites (Fig. 4). This indicates that EGFR’s intrinsic
Tyr kinase might be able to phosphorylate OGT. We sug-
gest that phosphorylation of OGT on Tyr by EGFR may
activate it to modify EGFR by O-GlcNAc in its catalytic
domain (Fig. 5).
Calcium levels play a significant role in the regulation of
EGFR’s multifunctionality. Calcium can activate PKC and
binding of calcium to CaM activates CaM kinases [3]. An
elevation of calcium activates PKC, which is able to
phosphorylate activated EGFR. Phosphorylated EGFR is
then translocated to recycling endosomes from where sig-
naling continues. Elevated calcium also binds to CaM and
activates CaM-II. Activation of CaM-II phosphorylates
EGFR in its cytoplasmic tail and desensitizes the receptor.
Depending on the signaling and the required conditions
EGFR signaling continues or is temporarily stopped. In
another scenario where calcium levels are low or limited,
OGT is activated. EGFR’s intrinsic Tyr kinase may be able
to phosphorylate OGT. Tyrosine phosphorylated OGT thus
modify EGFR by O-GlcNAc on Thr 654 and/or Ser 1046/
1047. It appears that OGT contribute to lysosomal targeting
of activated receptors in either recycling endosomes or to
late endosomes (Fig. 5).
These in silico investigations illustrate the role of the
complex interplay between phosphorylation and O-Glc-
NAc modification of EGFR is modulated by signaling.
Our results suggest that OGT plays a dual role in the
functional regulation of the EGFR, which could provide a
mechanism for achieving proper balance between the
activation and repression of EGFR signaling in cells. We
have highlighted the importance of PKC and CaM-II and
their interplay with OGT in the differential control of
EGFR’s signaling. We have predicted in silico the number
and location of Yin Yang sites within important structural
domains of the EGFR. An important goal for future
research will be to fully understand the structural and
functional aspects of these residues, and to elucidate the
different roles of PTM of the EGFR.
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